Trial Profile
Telaprevir-based triple therapy significantly decreases the serum alpha-fetoprotein level in chronic hepatitis C patients: A prospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- 01 Jul 2014 New trial record